Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast CancersHiu Tang, Srinivasan Madhusudan, Okezie Ofor et al.|Cancers|2023Cited by 17
Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC).Karen DeSouza, Sarah Khan, Daniel Yeo et al.|Journal of Clinical Oncology|2021Cited by 3